A5036028265- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- RNA Research and Splicing
- Chronic Lymphocytic Leukemia Research
- Kruppel-like factors research
- Nuclear Structure and Function
- Genomic variations and chromosomal abnormalities
- Ubiquitin and proteasome pathways
- Cellular transport and secretion
- Fibroblast Growth Factor Research
- RNA and protein synthesis mechanisms
- Cancer, Lipids, and Metabolism
- Breast Cancer Treatment Studies
- Research in Cotton Cultivation
- CRISPR and Genetic Engineering
- Liver physiology and pathology
- PI3K/AKT/mTOR signaling in cancer
Institut Gustave Roussy
2018-2025
Inserm
2018-2025
Université Paris-Sud
2020-2022
Université Paris-Saclay
2022
BackgroundThe cyclin-dependent kinase 4 (CDK4)/6 inhibitor Palbociclib is a new standard treatment in hormone-receptor positive breast cancer patients. No predictive biomarkers have been identified and no pharmacodynamics has properly described so far.Patients methodsPatients with early-breast were randomized 3 : 1 to oral palbociclib 125 mg daily for 14 days until the day before surgery versus treatment. Primary objective was antiproliferative response defined as natural logarithm of Ki67...
Abstract Background A current critical need remains in the identification of prognostic and predictive markers early breast cancer. It appears that a distinctive trait cancer cells is their addiction to hyperactivation ribosome biogenesis. Thus, biogenesis might be an innovative source biomarkers evaluated. Methods Here, fibrillarin ( FBL ) was used as surrogate marker due its essential role steps association with poor prognosis when overexpressed. Using 3,275 non-metastatic primary tumors,...
Abstract Pivotal role of immune response in the evolution triple negative breast cancer has been largely reported last decade. Our previous study highlighted HLF gene as part a four signature and was found to be negatively correlated with tumoral cells infiltration. We investigated more precisely its implication TNBC tumor development. Bioinformatics analysis publicly available patient datasets revealed that mesenchymal subtypes expressing low levels upregulation genes associated neutrophil...
Abstract Purpose: We compared the mutational profile of second breast cancers (SBC) following first ipislateral hormone receptor–positive patient-matched tumors to distinguish new primaries from true recurrences. Experimental Design: Targeted next-generation sequencing using Oncomine Tumor Mutation Load Assay. Variants were filtered according their allele frequency ≥ 5%, read count 5X, and genomic effect annotation. Whole genome comparative hybridization array (CGH) was also performed...
Rapalogs have become standard-of-care in patients with metastatic breast, kidney, and neuroendocrine cancers. Nevertheless, tumor escape occurs after several months most patients, highlighting the need to understand mechanisms of resistance. Using a panel cancer cell lines, we show that rapalogs downregulate putative protein kinase TRIB3 (tribbles pseudokinase 3). Blood samples small cohort treated confirmed downregulation TRIB3. Downregulation was mediated by LRRFIP1 independently mTOR...
Background: The mTOR pathway has a key role in regulating cell growth and is altered 70% of cancers. Rapalogs have become standard care patients with metastatic breast, kidney neuroendocrine Nevertheless, tumor escape occurs after several months most patients, highlighting the need to understand mechanisms action resistance. Thus, we aim identify new target genes rapalogs that could be used as biomarkers predict treatment efficacy, or therapeutic targets, overcome Methods: Expression levels...